Tumor Structure and Epidemiology
Among all neoplasms of the respiratory system, the vast majority are accounted for by lung cancer (from 90 to 95%). Carcinoids (about 5%) and tumors of mesenchymal origin (from 2 to 5%) are significantly less common.
In global statistics, the incidence exceeds 1 million new cases annually, accounting for more than 10% of all newly diagnosed malignant tumors. Geographically, the disease is distributed unevenly: about 58% of all clinical cases are registered in developed countries.
European statistics deserve special attention, where this pathology confidently ranks first in both incidence and mortality rates. By gender, the picture is as follows:
- Men: lung cancer accounts for 21% of all diagnosed tumors and causes 29% of mortality (overall accounting for about 30% of all cancer deaths in men).
- Women: the share in the tumor structure is 5%, and mortality is 9%. It is important to note the alarming dynamics: over the past twenty years, incidence and mortality among women have significantly increased. To date, mortality rates from this pathology in women have already exceeded those for breast cancer.
Terminology, Prognosis, and Social Significance
In specialized medical literature, the synonym "bronchogenic carcinoma" (or bronchogenic cancer) is often used. This term is not accidental: it clearly indicates the histogenesis of the neoplasm, emphasizing its origin from the epithelial lining of the bronchi and bronchioles.
The social significance of the problem is colossal. It is the most common malignant tumor and the leading cause of cancer death in industrialized countries.
The prognosis for patients remains extremely unfavorable, which is why lung cancer is considered the most fatal malignant tumor. The main problem lies in late diagnosis: in 75% of cases, the disease is detected at advanced stages when radical surgical treatment is no longer possible. As a result, survival rates remain extremely low, and even the use of complex modern therapy cannot fundamentally change the situation.
Conditions of Development and Risk Factors
The process of malignant transformation (malignization) has been confirmed both in experimental settings and in clinical practice. However, specific background conditions are required for its initiation and the concentration of carcinogenic substances.
The key factors contributing to tumor development are chronic inflammation and pneumosclerosis. Their mechanism of action lies in the fact that in damaged tissues, there is a violation of immunological control over mutated cells, as well as a failure of normal intercellular regulatory interactions.
Of greatest clinical importance as precancerous states are:
- Decompensated chronic inflammation and areas of pneumosclerosis forming in tuberculosis.
- Idiopathic fibrosing alveolitis (IFA).
- Scar changes in lung tissue remaining after a previous pulmonary infarction.
- Chronic inflammation localized around foreign bodies (in pathological anatomy, this condition is often called "scar cancer").
Morphogenesis and Molecular Basis
The pathogenesis of the tumor represents a complex chain of morphological changes. In foci of chronic inflammation and zones of pneumosclerosis, foci of proliferation of the bronchial, bronchiolar, and alveolar epithelium primarily arise. The cellular composition of these foci is very diverse: basal, ciliated, and mucous cells, as well as Clara cells and type II pneumocytes, are found within them.
With further progression of the pathological process, the following changes develop:
- Metaplasia and dysplasia of the bronchial and bronchiolar epithelium.
- Formation of adenomatosis foci accompanied by marked epithelial cell atypia.
- Atypical epithelial hyperplasia localized in specific oval and slit-like structures within zones of pneumosclerosis.
The described changes are of critical importance for the development of cancer from small bronchi and bronchioles. At the same time, controversial points remain in the scientific community; in particular, the possibility of cancer arising directly from transformed type II pneumocytes is actively debated. It is important to remember that the development of carcinoma de novo — that is, without any preceding precancerous changes — is also possible.
The molecular basis of pathogenesis is determined by a complex combination of morphological and molecular-genetic features. Key aspects here include the pathology of apoptosis processes and the identification of specific biomolecular and histogenetic markers, which include various genes, proteins, and hormones.